Biomedical Engineering Reference
In-Depth Information
64. Persons, D.L.,
hybridization: results
from the survey program of the College of American Pathologists.
et al.
, HER-2 fluorescence
in situ
Arch
Pathol Lab Med
, 2006.
130
(3): 325-331.
65. Varley, J.M.,
, Alterations to either c-erbB-2(neu) or c-myc proto-
oncogenes in breast carcinomas correlate with poor short-term
prognosis.
et al.
Oncogene
, 1987.
1
(4): 423-430.
66. Ross, J.S.,
, The HER-2 receptor and breast cancer: ten years of
targeted anti-HER-2 therapy and personalized medicine.
et al.
Oncologist
,
(4): 320-368.
67. Sorlie, T.,
2009.
14
, Gene expression patterns of breast carcinomas
distinguish tumor subclasses with clinical implications.
et al.
Proc Natl Acad
(19): 10869-10874.
68. Khleif, S.N., J.H. Doroshow, and W.N. Hait, AACR-FDA-NCI Cancer
Biomarkers Collaborative consensus report: advancing the use of
biomarkers in cancer drug development.
Sci U S A
, 2001.
98
Clin Cancer Res
, 2010.
16
(13):
3299-3318.
69. Hudziak, R.M.,
, P185HER2 monoclonal antibody has
antiproliferative effects in vitro and sensitizes human breast tumor
cells to tumor necrosis factor.
et
al.
Mol Cell Biol
, 1989.
9
(3): 1165-1172.
70. Pegram, M.,
, Inhibitory effects of combinations of HER-2/neu
antibody and chemotherapeutic agents used for treatment of human
breast cancers.
et al.
Oncogene
, 1999.
18
(13): 2241-2251.
71. Pietras, R.J.,
, Antibody to HER-2/neu receptor blocks DNA repair
after cisplatin in human breast and ovarian cancer cells.
et al.
Oncogene
,
(7): 1829-1838.
72. Sliwkowski, M.X.,
1994.
9
, Nonclinical studies addressing the mechanism
of action of trastuzumab (Herceptin).
et al.
Semin Oncol
, 1999.
26
(4 Suppl
12): 60-70.
73. Baselga, J.,
, Phase II study of efficacy, safety, and pharmacokinetics
of trastuzumab monotherapy administered on a 3-weekly schedule.
et al.
J
Clin Oncol
, 2005.
23
(10): 2162-2171.
74. Baselga, J.,
, Phase II study of weekly intravenous trastuzumab
(Herceptin) in patients with HER2/neu-overexpressing metastatic
breast cancer.
et al.
Semin Oncol
, 1999.
26
(4 Suppl 12): 78-83.
75. Tokuda, Y.,
, Dose escalation and pharmacokinetic study of a
humanized anti-HER2 monoclonal antibody in patients with HER2/
neu-overexpressing metastatic breast cancer.
et al.
Br J Cancer
, 1999.
81
(8):
1419-1425.
